TACTI-004 planned ~756 patients across >150 sites and enrolled 378 by February 2026, including squamous and nonsquamous NSCLC irrespective of PD-L1 status. Randomization compared eftilagimod alfa plus ...
Pixelgen's PNA delivers nanoscale spatial analysis of immune cell proteins at scale, as part of the company's Pixelgen Proxiome Kit. The technology is used by researchers looking for new avenues for ...
Candel Therapeutics Inc (NASDAQ:CADL) has reported updated clinical data showing extended survival outcomes from its ongoing ...
Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clinical trial, with 50% of 46 patients with ...
A Diaceutics report looks at when in the diagnosis, testing, and treatment process NSCLC patients lose out on access to precision medicine.
Epigenetic programming from prolonged undernutrition and terror can persist 3–4 generations, plausibly contributing to ...
Many hospitalized adults could benefit from linkage to dental care. This article describes a planned study to refer inpatients to community dental providers. Objectives: Previous research suggests ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results